GlassScriptPhysician profile
Kenyn Lawrence Koop
NPI 1124507439
$1,329.40
in general payments reported to CMS, 2019-2025
33 companies · $423 in 2025
The $423 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.08 · 2021: $29.88 · 2022: $14.85 · 2023: $207 · 2024: $602 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $190.99 | 2023-2024 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $137.85 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Radius Health, INC. | $107.80 | 2024-2025 | Tymlos |
| Lundbeck LLC | $99.88 | 2024-2025 | Vyepti |
| Merck Sharp & Dohme LLC | $77.08 | 2019-2024 | Keytruda |
| Glaxosmithkline, LLC. | $65.77 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Alexion Pharmaceuticals, INC. | $50.55 | 2024 | Ultomiris |
| Madrigal Pharmaceuticals | $48.89 | 2025 | Rezdiffra |
| Grifols USA, LLC | $44.68 | 2024-2025 | Gamunex-C, Prolastin-C Liquid |
| Neurocrine Biosciences, INC. | $39.85 | 2025 | |
| Tg Therapeutics, INC. | $32.03 | 2024 | |
| Eisai INC. | $31.08 | 2025 | |
| Ucb, INC. | $31.03 | 2025 | Rystiggo |
| Novartis Pharmaceuticals Corporation | $29.28 | 2023 | |
| Dexcom, INC. | $28.47 | 2023-2025 | Dexcom G6 Transmitter |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $25.72 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $24.56 | 2024 | |
| Organon LLC | $23.42 | 2025 | Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.45 | 2024 | Ofev |
| Sanofi-Aventis U.S. LLC | $21.38 | 2025 | |
| Daiichi Sankyo INC. | $20.61 | 2024 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $18.29 | 2021 | |
| Tolmar, INC. | $16.40 | 2025 | Jatenzo |
| Csl Behring | $16.22 | 2025 | Hizentra |
| Insightec,INC | $16.19 | 2025 | Exablate |
| Vertex Pharmaceuticals Incorporated | $15.39 | 2024 | |
| Amgen INC. | $15.03 | 2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $14.12 | 2025 | Airsupra |
| Medtronic, INC. | $13.59 | 2025 | Inceptiv |
| Exact Sciences Corporation | $13.29 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $13.26 | 2025 | Voquezna |
| Mallinckrodt Hospital Products INC. | $13.14 | 2023 | Acthar |
| The Binding Site INC. | $11.11 | 2025 | Freelite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenyn Koop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.